Companies: 10,795·Total market cap: $144.5T
Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc

BRNSNASDAQHealthcare● Active
$0.74
+$0.02(+2.49%)
Market Cap$30142398
P/E Ratio
52W High$2.92
52W Low$0.512

Barinthus Biotherapeutics plc (BRNS) Revenue

Annual & quarterly revenue history · segment & region breakdown

BRNS · revenue · updated Jun 9, 2026

Core revenue metrics

Barinthus Biotherapeutics plc trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
105 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Barinthus Biotherapeutics plc SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
BRNS revenue by year · BRNS revenue history · BRNS annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Barinthus Biotherapeutics plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Barinthus Biotherapeutics plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Barinthus Biotherapeutics plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

BRNS revenue · 4 questions

BRNS's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

BRNS revenueBRNS annual revenuewhat is BRNS revenueBRNS TTM revenue

Source: FMP · Barinthus Biotherapeutics plc SEC filings · GAAP · Barinthus Biotherapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026